Can disclosure hurt the translation of research?
All major clinical trials now include disclosures detailing who funded the study to ensure transparency. However, is it possible that this transparency is actually hurting research? One might assume that the methodological rigor of the study matters to physicians more than the disclosure. However, in a new study, researchers at Brigham and Women's Hospital (BWH) have found that pharmaceutical industry sponsorship of a research study negatively influences physicians' perceptions of the study and their willingness to believe and act on the research findings. This study will be published in the September 20, 2012 issue of the New England Journal of Medicine (NEJM).
"We found that physicians downgraded their perceptions of industry funded research similarly for high-quality studies and low-quality studies," explained Aaron Kesselheim, MD, JD, assistant professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at BWH, and principal investigator of this study.
The research team presented abstracts describing hypothetical clinical trials of three fictional, but potentially useful, new drugs to a national sample of board-certified internal medicine physicians. Each abstract was randomized to demonstrate high, medium, or low methodological rigor and randomized to report one of three disclosure variables: funding from a pharmaceutical company, funding by the National Institutes of Health (NIH), or no disclosure listed. The investigators then assessed physicians' impressions of the trials' rigor, their confidence in the results, and their willingness to prescribe the drugs.
"We found clear associations between the funding disclosure variations and physicians' perceptions of a trial's rigor and results," explained Dr. Kesselheim.
The results showed that physicians downgraded the credibility of industry-funded trials when compared with the same trials that had no funding listed, and to an even greater extent when compared with the same trials characterized as having NIH funding. The authors attributed these results to high-profile instances of unethical behavior by pharmaceutical companies sponsoring clinical research in the past decade.
Researchers emphasize that these findings have important implications. The pharmaceutical industry funds a substantial portion of clinical research, and a key determinant of the impact of a trial should be its methodological rigor, not its funding source, Dr. Kesselheim and his co-authors argue.
"While there is good reason to be extra vigilant about industry-funded research, if physicians are reluctant to trust all such research, this could hinder the translation of even high-quality industry-funded research into practice. Strategies such as greater transparency and independent review of trial data could be pursued to try to change such attitudes among physicians," Dr. Kesselheim suggested.
Journal reference: New England Journal of Medicine
Provided by Brigham and Women's Hospital
- Positive outcome no more likely in industry-funded trials Jul 05, 2012 | not rated yet | 0
- Drug trials funded by industry are more likely to publish favorable results Aug 02, 2010 | not rated yet | 0
- Clinical study of epilepsy drug may have been purely promotional Jun 27, 2011 | not rated yet | 0
- Patients, clinicians favor disclosure of financial ties to industry Apr 26, 2010 | not rated yet | 0
- Public disclosure of clinical trial results by Health Canada should be mandatory Aug 29, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
Early use of tracheostomy for mechanically ventilated patients not associated with improved survival
For critically ill patients receiving mechanical ventilation, early tracheostomy (within the first 4 days after admission) was not associated with an improvement in the risk of death within 30 days compared to patients who ...
Other 10 hours ago | not rated yet | 0
The decision to limit life support in patients in the intensive care unit (ICU) appears to be significantly influenced by physician practices and/or the culture of the hospital, suggests new findings from researchers at the ...
Other 12 hours ago | not rated yet | 0
Knee replacement surgery is a very common procedure. However, it does not always resolve function or pain in all the recipients of new knees. A study by Robert Barrack, MD and his colleagues from the Washington University ...
Other 14 hours ago | not rated yet | 0
Doctors are trained to think "common disease" when they meet patients in their practices, and as they rarely or never meet a rare disease, it often takes many years to reach the right diagnosis. A new search tool called FindZebra ...
Other 14 hours ago | not rated yet | 0
Delayed transfer to the intensive care unit (ICU) in hospitalized patients significantly increases the risk of dying in the hospital, according to a new study from researchers in Chicago.
Other 16 hours ago | not rated yet | 0
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
14 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
12 hours ago | 4.9 / 5 (11) | 0 |
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
8 hours ago | 3 / 5 (2) | 0
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
14 hours ago | 4.6 / 5 (7) | 0 |
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
9 hours ago | 5 / 5 (4) | 0 |
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
10 hours ago | 5 / 5 (1) | 0 |